Activation of receptor for advanced glycation end products - A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis

被引:641
|
作者
Schmidt, AM
Yan, SD
Wautier, JL
Stern, D
机构
[1] Columbia Univ Coll Phys & Surg, Dept Surg, Div Surg Sci, New York, NY 10032 USA
[2] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA
[3] Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA
[4] Columbia Univ Coll Phys & Surg, Dept Physiol, New York, NY 10032 USA
[5] Columbia Univ Coll Phys & Surg, Dept Cellular Biophys, New York, NY 10032 USA
[6] UFR Lariboisiere St Louis, Lab Biol Vasc & Cellulaire, Paris, France
关键词
glycoxidation; diabetes; nuclear factor-kappa B; inflammation; amyloid;
D O I
10.1161/01.RES.84.5.489
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily of cell surface molecules and engages diverse ligands relevant to distinct pathological processes. One class of RAGE ligands includes glycoxidation products, termed advanced glycation end products, which occur in diabetes, at sites of oxidant stress in tissues, and in renal failure and amyloidoses. RAGE also functions as a signal transduction receptor for amyloid beta peptide, known to accumulate in Alzheimer disease in both affected brain parenchyma and cerebral vasculature. Interaction of RAGE with these ligands enhances receptor expression and initiates a positive feedback loop whereby receptor occupancy triggers increased RAGE expression, thereby perpetuating another wave of cellular activation. Sustained expression of RAGE by critical target cells, including endothelium, smooth muscle cells, mononuclear phagocytes, and neurons, in proximity to these ligands, sets the stage for chronic cellular activation and tissue damage. In a model of accelerated atherosclerosis associated with diabetes in genetically manipulated mice, blockade of cell surface RAGE by infusion of a soluble, truncated form of the receptor completely suppressed enhanced formation of vascular lesions. Amelioration of atherosclerosis in these diabetic/atherosclerotic animals by soluble RAGE occurred in the absence of changes in plasma lipids or glycemia, emphasizing the contribution of a lipid- and glycemia-independent mechanism(s) to atherogenesis, which we postulate to be interaction of RAGE with its ligands. Future studies using mice in which RAGE expression has been genetically manipulated and with selective low molecular weight RAGE inhibitors will be required to definitively assign a critical role for RAGE activation in diabetic vasculopathy. However, sustained receptor expression in a microenvironment with a plethora of ligand makes possible prolonged receptor stimulation, suggesting that interaction of cellular RAGE with its ligands could be a factor contributing to a range of important chronic disorders.
引用
收藏
页码:489 / 497
页数:9
相关论文
共 50 条
  • [1] Human recombinant receptor for advanced glycation end products as a potential therapy of the diabetic vasculopathy
    Renard, C
    Wautier, JL
    THROMBOSIS AND HAEMOSTASIS, 1999, : 625 - 626
  • [2] Role of Receptor for Advanced Glycation End Products (RAGE) in Regression of Diabetic Atherosclerosis
    Senatus, Laura M.
    Lopez-Diez, Raquel
    Liu, Jianhua
    Li, Huilin
    Daffu, Gurdip
    Li, Qing
    Rahman, Karishma
    Vengrenyuk, Yuliya
    Barrett, Tessa
    Friedman, Richard
    Ramasamy, Ravichandran
    Fisher, Edward
    Schmidt, AnnMarie
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2017, 37
  • [3] Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy - Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats
    Wautier, JL
    Zoukourian, C
    Chappey, O
    Wautier, MP
    Guillausseau, PJ
    Cao, R
    Hori, O
    Stern, D
    Schmidt, AM
    JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (01): : 238 - 243
  • [4] Receptor for Advanced Glycation End Products, Reverse Transmigration and Impaired Regression of Diabetic Atherosclerosis
    Senatus, Laura M.
    Shen, Xiaoping
    Li, Huilin Li
    Daffu, Gurdip
    Rosario, Rosa
    Schmidt, Ann Marie
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2014, 34
  • [5] Activation of receptor for advanced glycation end products: A novel mechanism for monocyte activation in chronic renal failure.
    Hou, FF
    Ren, H
    Zhang, X
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 261A - 261A
  • [6] Role of advanced glycation end products on vascular smooth muscle cells under diabetic atherosclerosis
    Mao, Lin
    Yin, Ruili
    Yang, Longyan
    Zhao, Dong
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [7] Receptor for advanced glycation end-products-mediated inflammation and diabetic vascular complications
    Yamamoto, Yasuhiko
    Yamamoto, Hiroshi
    JOURNAL OF DIABETES INVESTIGATION, 2011, 2 (03): : 155 - 157
  • [8] Controlling the receptor for advanced glycation end-products to conquer diabetic vascular complications
    Yamamoto, Yasuhiko
    Yamamoto, Hiroshi
    JOURNAL OF DIABETES INVESTIGATION, 2012, 3 (02): : 107 - 114
  • [9] The Role of Advanced Glycation End Products in Diabetic Vascular Complications
    Rhee, Sang Youl
    Kim, Young Seol
    DIABETES & METABOLISM JOURNAL, 2018, 42 (03) : 188 - 195
  • [10] Advanced Glycation End Products (AGEs) and Diabetic Vascular Complications
    Yamagishi, Sho-ichi
    Nakamura, Kazuo
    Imaizumi, Tsutomu
    CURRENT DIABETES REVIEWS, 2005, 1 (01) : 93 - 106